Cargando…

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer

SIMPLE SUMMARY: We established an in vitro model for PARPi-resistant ovarian cancer by long-term olaparib exposure of either BRCA1-proficient or BRCA1-deficient cell lines. We describe that PARPi-resistant cells show a broad spectrum of cross-resistance toward other clinically relevant PARPis and ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klotz, Daniel Martin, Schwarz, Franziska Maria, Dubrovska, Anna, Schuster, Kati, Theis, Mirko, Krüger, Alexander, Kutz, Oliver, Link, Theresa, Wimberger, Pauline, Drukewitz, Stephan, Buchholz, Frank, Thomale, Jürgen, Kuhlmann, Jan Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417418/ https://www.ncbi.nlm.nih.gov/pubmed/37568590 http://dx.doi.org/10.3390/cancers15153774

Ejemplares similares

Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

PARPi after PARPi in epithelial ovarian cancer
por: Essel, K.G., et al.
Publicado: (2021)

Decoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity
por: Bemmerlein, Lila, et al.
Publicado: (2022)

Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis
por: Klotz, Daniel Martin, et al.
Publicado: (2022)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017)

FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer
por: Bachmann, Hagen Sjard, et al.
Publicado: (2022)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells
por: Melnikova, Margarita, et al.
Publicado: (2020)

[(18)F]PARPi Imaging Is Not Affected by HPV Status In Vitro
por: Guru, Navjot, et al.
Publicado: (2021)

Fully Automated, High-Dose Radiosynthesis of [(18)F]PARPi
por: Pacelli, Anna, et al.
Publicado: (2022)

Construction of PARPi Resistance-related Competing Endogenous RNA Network
por: Kong, Lili, et al.
Publicado: (2022)

Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer
por: Link, Theresa, et al.
Publicado: (2019)

Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer
por: Kuhlmann, Jan Dominik, et al.
Publicado: (2019)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
por: Klotz, Daniel Martin, et al.
Publicado: (2020)

The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro
por: Schott, Sarah, et al.
Publicado: (2017)

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines
por: Fedier, André, et al.
Publicado: (2022)

Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression
por: Link, Theresa, et al.
Publicado: (2017)

Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
por: Madariaga, Ainhoa, et al.
Publicado: (2020)

Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
por: Di Raimo, Tania, et al.
Publicado: (2020)

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
por: O’Sullivan, Julia, et al.
Publicado: (2023)

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
por: Kuhlmann, Jan Dominik, et al.
Publicado: (2012)

Low E2F2 activity is associated with high genomic instability and PARPi resistance
por: Rennhack, Jonathan P., et al.
Publicado: (2020)

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience
por: Moubarak, Malak, et al.
Publicado: (2022)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Diagnostic Benefit of the Detection of Mitotic Figures in Endometriotic Lesions
por: Wetzk, Michelle, et al.
Publicado: (2022)

Correction: Diagnostic Benefit of the Detection of Mitotic Figures in Endometriotic Lesions
por: Wetzk, Michelle, et al.
Publicado: (2023)

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer
por: Chebouti, Issam, et al.
Publicado: (2016)

MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment
por: Mori, Federica, et al.
Publicado: (2013)

PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer
por: Ambur Sankaranarayanan, Ramya, et al.
Publicado: (2022)

Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes
por: Todisco, Elisabetta, et al.
Publicado: (2022)

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
por: Giesen, Alexander, et al.
Publicado: (2023)

HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients
por: Li, Lei, et al.
Publicado: (2023)

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy
por: Chebouti, Issam, et al.
Publicado: (2017)

Mesenchymal stromal cell-associated migrasomes: a new source of chemoattractant for cells of hematopoietic origin
por: Deniz, Ilker A., et al.
Publicado: (2023)

Discriminating radiation injury from recurrent tumor with [(18)F]PARPi and amino acid PET in mouse models
por: Donabedian, Patrick L., et al.
Publicado: (2018)

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
por: Sun, Chenggong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s0a53a606ln349hs0ucthaglgt